Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan Sells GPCR Portfolio to MBL, Plans to Continue Antibody Line

NEW YORK, Feb. 21 (GenomeWeb News) - LifeSpan BioSciences has sold "most of its existing catalog" of antibodies to Medical and Biological Laboratories International, LifeSpan confirmed today.

 

The Massachusetts-based subsidiary of Nagoya, Japan-based MBL bought 921 antibodies to about 400 different protein targets, including 800 GPCR antibodies.

 

"MBL has a broader reach in terms of selling this product," LifeSpan CEO Joseph Brown said.  

 

Brown said LifeSpan plans to continue developing antibodies to gene-target proteins and will consider future distribution deals with MBL.

 

Financial details of the deal were not available.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.